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Stability of Extemporaneously Prepared Rufinamide Oral Suspensions
Abstract
Background:
Rufinamide is an oral antiepileptic drug indicated for adjunctive therapy in treating generalized seizures
associated with Lennox-Gastaut syndrome. Currently, rufinanide is available as 200-mg and 400-mg
tablets. A liquid dosage form does not exist at the present time. Lack of a suspension formulation may
present an administration problem for many children and adults who are unable to swallow tablets. The
availability of a liquid dosage form will provide an easy and accurate way to measure and administer the
medication.
Objective:
To determine the stability of both sugar-containing and sugar-free rufinamide suspensions over a 90-day
period.
Methods:
A suspension of rufinamide 40 mg/mL was prepared by grinding twelve 400-mg tablets of rufinamide
tablets in a glass mortar. Sixty milliliters of Ora-Plus and 60 mL of either Ora-Sweet or Ora-Sweet SF
(sugar free) were mixed and added to the powder to make a final volume of 120 mL. Three identical
samples of each formulation were prepared and placed in 60-mL amber plastic bottles and were stored at
room temperature. A 1-mL sample was withdrawn from each of the 6 bottles with a micropipette
immediately after preparation and at 7, 14, 28, 56, and 90 days. After further dilution to an expected
concentration of 0.4 mg/mL, the samples were assayed using high-performance liquid chromatography.
Stability was defined as the retention of at least 90% of the initial concentration.
Results:
At least 90% of the initial rufinamide concentration remained throughout the 90-day study period in both
preparations. There were no detectable changes in color, odor, taste, and pH and no visible microbial
growth.
Conclusions:
Extemporaneously compounded suspensions of rufinamide 40 mg/mL in a 1:1 mixture of Ora-Plus and
Ora-Sweet or Ora-Sweet SF were stable for at least 90 days when stored in 59-mL amber polypropylene
plastic bottles at room temperature.
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ABSTRACT
BACKGROUND: Rufinamide is an oral antiepileptic drug indicated for adjunctive
therapy in treating generalized seizures associated with Lennox-Gastaut syndrome.
Currently, rufinamide is available as 200-mg and 400-mg tablets. A liquid dosage form
does not exist at the present time. Lack of a suspension formulation may present an
administration problem to many children and adults who are unable to swallow tablets.
The availability of a liquid dosage form will provide an easy and accurate way to
measure and administer the medication.
OBJECTIVES: To determine the stability of both sugar-containing and sugar-free
rufinamide suspensions over a 90-day period.
METHODS: A suspension of rufinamide 40 mg/mL was prepared by grinding twelve
400-mg tablets of rufinamide tablets in a glass mortar. Sixty milliliters of Ora-Plus and
60 mL of either Ora-Sweet or Ora-Sweet SF were mixed and added to the powder to
make a final volume of 120 mL. Three identical samples of each formulation were
prepared and placed in 2-oz amber plastic bottles and were stored at room temperature.
A 1-mL sample was withdrawn from each of the six bottles with a micropipette
immediately after preparation and at 7, 14, 28, 56 and 90 days. After further dilution to
an expected concentration of 0.4 mg/mL, the samples were assayed using highperformance liquid chromatography. Stability was defined as the retention of at least
90% of the initial concentration.
RESULTS: At least 90% of the initial rufinamide concentration remained throughout
the 90-day study period in both preparations. There were no detectable changes in color,
odor, taste and pH and no visible microbial growth.
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CONCLUSION: Extemporaneously compounded suspensions of rufinamide, 40
mg/mL, in a 1:1 mixture of Ora-Plus and Ora-Sweet or Ora-Sweet SF were stable for at
least 90 days when stored in 2-oz amber polypropylene plastic bottles at room
temperature.
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INTRODUCTION
Lennox-Gastaut syndrome (LGS) is an age-specific disorder characterized by the
classic triad of epileptic seizures (i.e. atonic, tonic and atypical absence), slow spikewaves in the waking electroencephalogram (EEG) and fast rhythmic bursts during sleep
and moderate-to-severe cognitive dysfunction.1,2 To date, the optimal therapy for LGS
remains uncertain and often includes a combination of various antiepileptic drugs
including valproic acid, lamotrigine, topiramate and felbamate.1 Rufinamide is a new,
oral antiepileptic medication indicated for adjunctive therapy in treating generalized
seizures associated with LGS in children 4 years and older and adults. Currently,
rufinamide is available in a tablet formulation of 200-mg and 400-mg.3 A liquid dosage
form does not exist at the present time. Lack of a suspension formulation may present an
administration problem to many children and adults who are unable to swallow tablets.
In addition, a weight-based dosage regimen is recommended by the manufacture upon
initiation and titration in the pediatric population. The availability of a liquid dosage
form will provide an easy and accurate way to measure and administer the medication to
an individual patient.
The purpose of this study was to determine the short-term stability of an
extemporaneously compounded oral liquid dosage form of rufinamide prepared from
commercially available tablets.
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METHODS
Suspension Preparation. Twelve 400-mg rufinamide tabletsa were thoroughly
triturated in a glass mortar. Sixty mL of Ora-Plus suspension vehicleb was added to the
mortar and triturated with the drug powder until a homogeneous suspension was
obtained. Sixty mL of Ora-Sweetc or Ora-Sweet SFd flavoring syrup was then added to
the suspension and mixed thoroughly to obtain the final suspension (40mg/mL). A
preliminary taste assessment of the two suspensions was performed by two volunteers.
No unpleasant taste was reported, and therefore, no additional formulation adjustments
were necessary. Details of the compounding procedure are provided in the appendix.
Stability Study. Each of the two suspensions prepared above was divided equally
into three samples (~ 40 mL each) and transferred into 2-oz amber polypropylene plastic
bottles closed with child resistant caps.e All samples were stored at room temperature
(23-25C) and assayed after 0, 7, 14, 28, 56 and 90 days of storage. At each time point,
the samples were subjected to visual inspection and reversed phase high-performance
liquid chromatography (RP-HPLC) analysis. In addition, pH measurement was
performedf for all samples on day-0 and day-90. Microbiology testing was not included,
because each commercial vehicle already contained effective preservatives. The RPHPLC data was used to calculate the percentage of the initial drug concentration
remaining at each time point. Stability was defined as the retention of at least 90% of the
initial concentration.
RP-HPLC Method. Each bottle was shaken thoroughly by hand for approximately
15 seconds immediately before sampling. A 1-mL sample was withdrawn from each
bottle and diluted to 100-mL in a volumetric flask with sample diluent consisting of
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methanol and water (80:20 v/v). The expected rufinamide concentration after dilution
was 0.4 mg/mL. The samples were stirred for one hour and sonicated for one hour. Due
to the viscous nature of the suspension vehicle, it was necessary to disperse the
suspension in diluent by stirring prior to sonication. Approximately 3 mL of each sample
was withdrawn and filtered through a 0.45 µm syringe filterg to remove insoluble
excipients. The filtered samples were assayed by RP-HPLC.
RP-HPLC analysis was conducted using a Shimadzu model LC-2010A instrumenth
equipped with a C18 columni maintained at 40°C and UV detector set at 230 nm. The
mobile phase consisted of methanol and water (35:65 v/v) with 1 mL/L trifluoroacetic
acid delivered at a flow rate of 0.5 mL/min. It was filtered and degassed on-line before
use. For analysis, 10 µL of each sample was injected by the autosampler. The data was
collected and processed by the Shimadzu LCSolution software. The retention time of
rufinamide was 10.9 minute.
Standards of rufinamide at 0.2, 0.3, 0.4, 0.5, and 0.6 mg/mL were prepared in the
same sample diluent (methanol:water 80:20 v/v) for the RP-HPLC method calibration.
Because the pure drug substance of rufinamide was not available commercially, the
standards were prepared by using the crushed tablet powder from the commercial tablet
dosage form.a The average weight of the 400-mg strength rufinamide tablets was
determined to be 740 mg, and calculations were performed to ensure the proper amount
of crushed tablet powder was used to prepare each standard. Once the diluent was added
to the crushed tablet powder, the samples were sonicated for 15 minutes followed by 2
hours of stirring to ensure full extraction of the drug substance into the diluent. The
samples were filtered through 0.45 µm Nylon syringe filtersg to remove the insoluble
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tablet excipients prior to the RP-HPLC analysis. A calibration curve was produced by
linear regression of the peak area of rufinamide against rufinamide concentration. The
standard curve was linear (r2 = 0.998) over the working range of concentrations. The
between-day and within-day coefficients of variation for the RP-HPLC assay were 0.82%
and 0.67%, respectively.
A forced degradation study of rufinamide was conducted under extreme pH and
oxidative stress conditions in order to verify the stability indicating ability of the RPHPLC assay. Four 0.04 mg/mL rufinamide solutions were first prepared by diluting a 0.4
mg/mL rufinamide standard solution (see paragraph above) with sample diluent
(methanol: water 80:20 v/v). Sample #1 was adjusted to pH 2 using 1 N hydrochloric
acid. Sample #2 was adjusted to pH 12 with 1 N sodium hydroxide. Sample #3 and
Sample #4 were each spiked with 3% hydrogen peroxide (final concentration). Samples
#1 – 3 were incubated at 60°C for 24 hours. Sample #4 was exposed to direct sunlight for
30 days. RP-HPLC analysis was conducted at the end of each sample treatment.
Approximately 4%, 19%, 34%, 95% degradation of rufinamide was observed in
Samples# 1, 2, 3, and 4, respectively. No interfering peaks from the degradation products
were observed. In Sample #2, an unidentified degradation product peak was noted at 1.3
relative retention time to rufinamide. No major degradation product peaks were observed
for Samples #3 & #4 despite the significant amount of loss of parent drug. It was
speculated that (a) the oxidation products were polar and co-eluted with the solvent front;
(b) the oxidation products did not absorb UV light at 230 nm.
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RESULTS AND DISCUSSION
Rufinamide is commercially available as tablet dosage forms in two strengths, 200-mg
and 400-mg.3 Based on composition listed in the labeling,3 the rufinamide tablets are
formulated as conventional immediate release oral tablets containing common excipients
and non-functional film coating. Therefore, compounding these tablets into powder or
suspension dosage forms is not expected to alter the drug bioavailability or therapeutic
effectiveness significantly.
The 40 mg/mL rufinamide suspensions were prepared in this study using 1:1 mixtures
of commercially available vehicles, i.e. Ora-Plus with either Ora-Sweet or Ora-Sweet SF
(sugar free). The Ora-Plus was intended as the main suspending vehicle; the Ora-Sweet
and Ora-Sweet SF syrups provided flavoring and sweetness for taste masking. All
vehicles contained effective preservatives to prevent microbial growth.
The RP-HPLC data of the compounded suspensions were summarized in Table 1.
Both suspensions remained stable (at least 90% of initial concentration) throughout the
90-day study period. In addition, there was no appreciable change in the pH from the
initial mean + S.D. in any of the samples made with Ora-Sweet (pH 4.43 + 0.08) or in
those prepared with Ora-Sweet SF (pH 4.32 + 0.07) throughout the study period. There
was no visible microbial growth in any samples.
The palatability of the compounded suspensions was also assessed and confirmed to
be satisfactory. No additional taste masking agents are necessary.
It is noteworthy that the two strengths of rufinamide tablets share the same excipient
composition.3 The excipients:drug ratio was also identical in the two strengths of tablets
based on the average tablet weight determined in this study (370 mg for the 200-mg
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strength tabletsj and 740 mg for the 400-mg strength tabletsa). Therefore, the 200-mg
strength tablets can also be used to compound the same suspensions described in this
study following the procedures in the appendix.

CONCLUSION
Extemporaneously compounded suspensions of rufinamide, 40 mg/mL, in a 1:1
mixture of Ora-Plus and Ora-Sweet or Ora-Sweet SF were stable for at least 90 days
when stored in 2-oz amber plastic bottles at room temperature.
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FOOTNOTES
a

Rufinamide (Banzel®) 400-mg tablets. Eisai Co., Ltd.; Woodcliff Lake, NJ, lot
004157.

b

Ora-Plus suspending vehicle. Paddock Laboratories, Minneapolis, MN, lot 8384265.

c

Ora-Sweet flavored syrup vehicle. Paddock Laboratories, lot 8384261.

d

Ora-Sweet SF flavored sugar free vehicle. Paddock Laboratories, lot 8374196.

e

Two-oz amber prescription bottles with child-resistant caps. Apothecary Products,
Burnsville, MN.

f

SevenEasy pH meter. Mettler-Toledo Inc., Columbus, OH.

g

Syringe filter, Nylon, 0.45 µm, 13-mm. Fisher Scientific, Suwanee, GA.

h

HPLC 2010A with LCSolutions. Shimadzu Scientific Instruments, Marlborough, MA.

i

Symmetry C18 column (3.5-μm particle size, 4.6 mm x 150 mm). Waters Corp.,
Milford, MA.

j

Rufinamide (Banzel®) 200-mg tablets. Eisai Co., Ltd.; Woodcliff Lake, NJ, lot
004156.
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Appendix – Procedure for compounding rufinamide suspension, 40 mg/mL (120 mL
batch):
1. Count out twelve 400-mg rufinamidea tablets (or twenty-four 200-mg rufinamide
tablets).
2. Crush the tablets from Step 1 in a glass mortar and triturate to a fine powder.
3. Add 60 mL of Ora-Plusb to the rufinamide powder from Step 2 via geometric dilution
until a smooth suspension is obtained.
4. Add 60 mL of Ora-Sweetc or Ora-Sweet SFd to the suspension from Step 3 and mix
well.
5. Transfer the mixture into a proper amber plastic prescription bottle.
6. Label the bottle “Shake Well Before Use” with an expiration date of 90 days after
preparation.
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Table 1.
Stability of Rufinamide 40 mg/mL in Two Vehicles at Room Temperature
Suspensiona

% Initial Concentration Remaininga

Actual Initial
Drug

Day 7

Day 14

Day 28

Day 56

Day 90

Concentrationa
(mg/mL)
Rufinamide,
Ora-Plus,
Ora-Sweet

41  1.7

103  1.4

99  0.0

97  1.4

100  1.4

92  1.4

Rufinamide,
Ora-Plus,
Ora-Sweet

41  0.0

104  6.5

100  1.4

100  2.9

100  3.8

101  0.0

a

= Mean  S.D. for three samples (n=3).

